Aoxing gets Chinese OK for angina drug

China Aoxing Pharmaceutical, a company specializing in research, development, manufacturing and marketing of narcotic and pain-management  products, has received a new production license for isosorbide  mononitrate injection from the China State Food and Drug  Administration for treatment of angina pectoris, myocardial  infarction, of chronic congestive heart failure, pulmonary  hypertension and related coronary artery disease. "Angina along with  coronary artery disease is a leading health problem among people over  the age of 50. Around 30 million people in China suffer from angina.  Isosorbide mononitrate is an effective intravenous injection drug in  hospitals to treat this public heath problem," said Juan Yue Han, chief  executive of China Aoxing.